

A Brief Overview of Ribonucleic Acid Interference (RNAi) for Combating Immune Disorders

Manisha Rastogi^{*1}, Sanjiv Mittal², Sushma Chaturvedi³, Pallavi Srivastava⁴

¹ School of Biomedical Engineering, Shobhit Institute of Engineering and Technology, Meerut, India

² Department of Medical, RIMT University, Mandi Gobindgarh, Punjab, India

³ Department of Pharmacology, SGT College of Pharmacy, Gurugram, Haryana, India

⁴ Department of Biotechnology, Sanskriti University, Mathura, Uttar Pradesh, India

ABSTRACT

In almost all human cells, the RNA interference (RNAi) system controls mRNA stability as well as translation. While tiny dsRNA particles are effective in inducing RNAi silence of particular genes, their clinical application has been fraught with difficulties about safety and efficacy. However, in August 2018, the field entered a new phase with the approval of patisiran, the very initial RNAi-based medicine, by the US Food & Drug Administration. Rapid advancements in our knowledge of RNAi-based processes have led to the use of this potent technique in gene function research as well as therapeutic applications for disease treatment. Two-dimensional pharmaceutical designs for RNAi-based treatments rely solely on the finding of excellent Watson-Crick base pairing between the RNAi guide strand and the target, allowing for fast construction and testing of RNAi triggers. Despite the great specificity of activity, siRNA may produce a series of untargeted consequences, because of the toxicity they cause, prohibit their usage at large dose. We address important breakthroughs in the development and design of RNAi medicines that led to this historic accomplishment, the present status of clinical pipeline, and possibilities for future advancements, including new RNAi pathway therapeutics that use mechanisms other than post-translational RNAi silencing.

Keywords: Adverse Effect, Binding, Complementary, Expression, Gene, Interference, RNA

HOW TO CITE THIS ARTICLE: Manisha Rastogi, Sanjiv Mittal, Sushma Chaturvedi, Pallavi Srivastava, A Brief Overview of Ribonucleic Acid Interference (RNAi) for Combating Immune Disorders, J Res Med Dent Sci, 2022, 10(S1): 118-123. A Brief Overview of Ribonucleic Acid Interference (RNAi) for Combating Immune Disorders, J Res Med Dent Sci, 2022, 10(S1): 118-123

Corresponding author: Manisha Rastogi

e-mail ✉: manisha.rastogi@shobhituniversity.ac.in

Received: 02/05/2022, **Manuscript No.** JRMDS-22-58456;

Editor assigned: 04/05/2022, **PreQC No.** JRMDS-22-58456(PQ);

Reviewed: 15/05/2022, **QC No** JRMDS-22-58456;

Revised: 18/05/2022, **Manuscript No.** JRMDS-22-58456 (R);

Accepted: 23/05/2022, **Published:** 15/06/2022

INTRODUCTION

RNA interference (RNAi) is a basic biological process for suppressing gene expression that may be used to create novel medicines. Reduced expression of pathogenic proteins via RNAi is relevant to all types of biological targets, many of which are difficult to regulate selectively using small molecules as well as peptides in conventional pharmacological methods. As a result, RNAi therapies as a class of drugs have the potential to revolutionize contemporary medicine. RNAi is a process in which the target mRNA is cleaved enzymatically, resulting in a reduction in the quantity of the associated protein, and selectivity is a critical aspect of the mechanism. Synthetic

short interfering RNAs (siRNAs) take use of the naturally occurring RNAi process in a consistent and predictable way in terms of activity extent and duration [1]. Additionally, viral delivery of small hairpin RNAs (shRNAs) may be used to control RNAi. Both non-viral siRNA administration and viral shRNA delivery are being investigated as possible RNAi-based medicinal methods.

Small interfering RNAs (siRNAs) are by far the most successful class of RNA-based medicinal nucleotide drugs due to the catalytic mode of action as well as the capacity of single siRNA molecules to deactivate multiple specific RNA molecules in a sequential way. Important success had been achieved for creation of clinical siRNAs due to finding of RNA interference (RNAi) and also it leads to synthesis of very first oligomer RNAs that induce RNAi in human cells. Chemical compositions of RNA are being created to enhance their activity and stability in biological fluids; progress has been made in developing techniques for siRNA distribution to cells. Numerous siRNA-based medicines are now undergoing clinical studies, and one,

patisiran (Onpatro), has been authorized for clinical usage. However, siRNAs' extraordinary potential for therapeutic agents has still not been completely realized. Numerous unresolved issues remain: it is critical to establish an efficient method of distributing siRNAs to different cell types; it is also required to produce customized siRNAs which are stable, efficiently silence target RNAs, as well as have no adverse effects. These issues arise as a result of siRNAs' characteristics as big, *polyanionic* particles that really are volatile in biological conditions and susceptible of eliciting undesired immune reactions whenever they enter cells.

RNAi introduction happens in double RNA (dsRNA) reaches the cell, such as whenever transfected by dsRNA, infected by viruses that include RNA, or when endogenous forming of RNA in cells results in transposon or non-encoding. The mechanism of RNAi is separated into two stages: during the first stage (start phase), long dsRNA is split into siRNAs, small double stranded RNAs (21–23 bp), with two nucleotides protruded only at end of 3'. A RNA-induced silencing complexes (RISC) develops throughout the second phase (effector phase). After the activation, the target mRNA is recognized and sequence-specific cleaved. It is demonstrated that RNAi may be induced in *mammalian* cells by manufactured siRNAs, which imitate dsRNA Dicer fragmentation products; the RNAi process simply requires the stage of the effectiveness.

The R2D2 proteins (in *Drosophila*) and its analogous protein (in many other species), that includes two dsRNA interacting domains as well as siRNA necessary domain of the dicer is binding in the initial phase of RISC construction. R2D2 identifies and links the thermodynamically stable 5' end of a duplex, allowing for subsequent binding by Dicer, because double stranded RNA-binding region has 3' overhang specificity. The intermediate loading complex RISC (RLC) is thus generated [2]. Dicer binds via *argonaute-2* (Ago2) after creation of the RLC, probably with the involvement of PAZ domains.

At the last phase of the RISC arrangement, Ago2 cuts one of several siRNA strands ("passenger strand") and causes the construction of active RISC* to be dissociated. The essential characteristics of a RISC activated are the Ago2 and the residual siRNA strand ("guide strand"). A variety of additional proteins could be components of such a complex, though. The choice of a strand included within RISC* is ascertained by the Dicer-R2D2 heterodimer orientation compared to siRNA. The R2D2 associates with both ends of thermodynamically stable duplex and most energetic siRNAs have a 5 prime thermostatic end of the sense strand than that of the 5 prime end of a antisense strand. Ago2 breaks both of the siRNA cargo strand as well as the specific mRNA, although siRNA strand separation without cleavage may be accomplished out. In addition, Human Ago2 is believed to induce strand dissociation, primarily via a mechanism that does not need its cleavage, thus the overall melting point in the duplex may contribute to the effectiveness of siRNA interfering activities.

The mRNA targeting is recognized by RISC* at various stages, in which the "seed" area (the 2 to 8 nuclear siRNA region on the 5' end of the anti-seed beach) plays a key role. First, the sequencing of nucleotide bases (2–4 nucleotide from 5' terminus of a siRNA strands) first is screened. Once the triplet has been identified, the fifth nucleotides from the 5' fiber end binds with both the target mRNA, that helps alter the conformational and opens nucleotides 6–8 as well as 13–16 for engagement (Figure 1). The additional contact between the siRNA strand and the mRNA offers a beneficial orientation to separate the mRNA from nucleotides 10-11 in relation to the 5' terminus of a siRNA, that happens through the Ago 2 PIWI domain [3]. After breaking and disconnecting from the complexes, ribonucleases destroy the target RNA and siRNA passenger strand. Released RISC* may participate catalytically in future cleavage cycles.




Figure 1: Critical nucleotide positions in siRNAs [4].

Because of the strong affinity of RISC* to ss RNA the RISC* binding efficiency having target mRNA is nearly higher than with the anti-sense *oligodeoxynucleotides*, which only interact in the same sequence with the target mRNA. So, siRNA levels are two to three orders smaller opposed to antisense oligonucleotides when an effective reduction in target gene expression is detected.

DISCUSSION

Principle of RNA interference

Interference with RNA has most probably developed as a method for the removal of undesirable foreign genes by cells. Foreign genes are frequently available in significant cells, as *progeny virions*, signal transduction or as plasmid, scientifically inserted in the procedures for cell transfected. It is known for many decades that perhaps the expression level of transgenes typically declines with the increasing amount of products in the cell and that the presence of transgenes may also inhibit indigenous homologous genes. Although genetic silencing may be carried out at level of transcription a significant method of gene suppression is now known post-transcription, and the main method of this PTGS is the RNAi, the selected destruction of the siRNAs mRNAs. These RNAi PTGS may develop extremely quickly with proteins for multiple genes and are reduced within hours. Based on these and other discoveries originally reported in plant research, RNAi appears to have developed as a means of protecting cell membrane against infectious diseases.

Post-transcriptional gene silencing via RNA interference discovery

PTGS and RNAi are found in genetic transformation investigations of *eukaryotic* cells, mostly plants and worms, where it was been shown mRNAs also for coded transgene alone or along with mRNAs are very low or absent for homologous gene expression, due to the high rate of transcription. Transgenes insert in the genome of plants via recombination in a seemingly random way such that now the copy number inserted, the chromosome position and location of the chromosomal differ across transformants [5]. The discovery of an opposite connection between the copy number and the gene expression level indicated that an increasing copy number of the certain gene causes the gene to remain silent.

Initially, gene silence was believed to be caused to decreased gene transcription owing to interaction among closely connected copies leading to the creation of secondary structures promoting methylation as well as restriction of transcription. Subsequent investigations have shown that transcriptional gene silence (TGS) may also happen in trans, such that single transgenic may be silenced by either crossover or by transformations. The proposal was then made that a silencing RNA should be generated by one locus that would somehow silence some other gene using a method that would include RNA-mediated transcription restriction. Even though some results were compatible with transcriptional silence mechanisms, other data indicated that PTGS was involved.

The existence and separation in siRNAs of about 23 nucleotides of double-stranded RNAs (DRNAs) was established, and it was subsequently demonstrated that the production of dsRNAs with sequences matching to open receive notification in plants leads in PTGS. The selective silence of these genes in *C* also leads in the production of dsRNAs having sequence comparable to that of endogenous genes. Taken together, the *A* studies. *Elegans* have shown that the same RNA degrading mechanism may start both TGS and PTGS – TGS occurs if dsRNA contains promoter sequences, while PCGS happens if dsRNA includes encoding sequences. While the degrading of dsRNA is similar for both gene silencing methods, the findings also showed that TGS and PTGS-mediated dsRNA require different specialized processes. While RNAi has first been identified in plants as a PTGS mechanism and could have developed as a cellular defensive mechanism versus foreign DNA as well as RNA, it is quite apparent that RNAi is often used, though not all eukaryotic cells, for regulating endogenous gene expression. In 1998, dsRNA was shown to be considerably more efficient in suppressing expression of genes in *C. Elegans* than RNA with a single beach. The very first study of the application of RNAi as a biological tool in experimentally generated PTGS was extremely powerful and surprisingly PTGS happened not just in worm to whom dsRNA has been given, but also in its offspring. It was subsequently shown that endogenous mRNA had been the target of the dsRNA, the injection

after transcription, and that the targeted mRNA was being degraded. Surprisingly, the dsRNA was found to be efficient at extremely low concentrations, which resulted in a copy number far higher than the amount of dsRNAs available in the cell. Furthermore, the removal of the protein coded with the specific mRNA continued through several cycles of cellular division. The last two findings clearly indicate that cells have a way to enhance the RNAi process. The RNAi process cannot only be maintained inside cells with a similar lineage, but also across cells, as demonstrated in *C. Elegans* wherein dsRNA infusion into the gut causes the targeted gene to remain silent in all the F1 progeny cells of this worms [6]. In fact dsRNA may cause PTGS if worms are absorbed into a dsRNA solution, or the worms were fed dsRNA-expressing bacteria. A hydrophobic protein named SID-1 has recently been discovered as a potential RNA intercellular transfer mediator.

Molecular mechanism of RNAi

The RNase Dicer triggers RNAi by cleaning RNA targets in double-stranded pieces of about 21 to 25 nucleotide bases. Most siRNA sequences are integrated into a protein termed the RNA-complex (RISC; Figure 2). *Argonaute 2* (Ago2) has been identified as the RISC protein responsible for the cleavage of mRNA and the crystallite size of Ago2, which revealed critical interactions, was published.




Figure 2: Cellular mechanism of RNA interference [7].

Long double-stranded RNA (dsRNA) is divided into a tiny interference RNA via enzyme *Dicer* (siRNA). Such siRNAs are included in the silencing complex for RNA induced (RISC), where even the strands are split. The guiding or antisense strands RISC looks for complementary mRNA sequences and binds them. These mRNA segments are subsequently separated by the RISC enzyme *Argonaute*, which results in down-modulation of mRNA. A, *athenosine* A (Figure 2). RNA interferes mostly inside the cell cytoplasm and is initiated by the incorporation of a two-stranded nucleotide towards cytoplasm of cell (Figure 2). The process is induced by stimulation of two main molecules, these early activities of the Dicer endonuclease (family enzyme RNase III), as well as the activities of a Silent Interfering RNA (RISC). The endonuclease Dicer reaction is accountable for the division of the long ds nucleotide into small interference RNAs (si) with a ds length of twenty one to twenty three

nucleotides (nt) [8]. RISC then unravels siRNA with a helicases and then attaches towards the free complementary strand.

This complex may recognize and destroy the particular complementary strand of mRNA with the assistance of the *Argonaute 2* protein, one of its main components. This results in the loss and inhibition of translation and protein synthesis of the mRNA which is complementary to the analogous strands of the initial dsRNA inserted in the *cytoplasm*s. Initial studies were effectively manipulated by the insertion of dsRNA in the cytoplasm of plants and invertebrates. However, comparable methods in mammalian cells resulted in the activation of interferon reaction and cellular damage before Dicer cleared. Elbashir et al. only disclosed an alternate RNAi induction technique in mammalian cells in 2001. By introducing siRNAs with a length of less than 30 base pairs, they effectively evaded interferon responses and triggered the destruction of the RISC system and mRNA in human cells.

Likewise, it has been studied how the insertion of just a few RNA strands leads in a significant excess of target mRNA. One theory proposed a class of RNA-dependent RNA (RdRp) polymerases using the goal of mRNA as a pattern and principal siRNAs cleaved as primers. These generate a secondary siRNA population, which leads to a rise in the quantity of active RISC multiplexes produced, then splice of mRNA. In *Arabidopsis*, *C. elegans*, *dictyostelium* and *neurospora* members of such RdRp family have indeed been discovered; and not *Drosophila* and mammals. Other proposed causes contains fact which Dicer is cutting dsRNA in shorter lengths, boosting the quantity of siRNAs ten to twenty times, and using a catalytic mechanism, RISC itself works as a multiple-turn enzyme and recycles synthesised siRNAs previously. The latter 2 would be plausible explanations for *Drosophila* and mammals lacking RdRp and therefore mechanisms for RNAi replication. Natural function of RNA interference is to defend plant as well as nematode from viral infections invasion. When infected, RNA viruses produce double-stranded (ds) RNA molecules whether for initiating or for replication, but these were the molecules which may enable the host RNAi defense system to be activated (Figure 3). This causes the viral RNA to degrade, which prevents viral replication. Plants deficient in RNAi which show hypersensitivity towards viral illness are emphasized in this phenomenon.




Figure 3: Demonstration of already tested applications of RNA interference [9].

Certain animal and vegetable viruses, such as Potato Virus X, also are known to generate proteins that inhibit host-induced RNA silence. Such proteins have demonstrated the effectiveness of viral propagation inside the host. Further research on its particular characteristics has been done after the discovery of the RNAi phenomena in plants, invertebrate as well as *mammalian* cells. Experiments were carried out utilizing nematodes to evaluate its potential for systemic propagation. They were fed, bathed or administered with a rich dsRNA mixture, leading to skin RNA gene silencing in all instances. Although there was no obvious method underlying this mechanism [10], a membrane peptide Sid-1 that allows passive cell absorption of dsRNA, which may play an active role in the RNAi dispersion, was discovered.

RNAi silencing effects in plants as well as invertebrates have been reported, but once again the exact principle remains unclear. As a consequence of these many studies, it was able to artificially manipulate RNAi in cultivated *mammalian* cells and its maximum ability for in vivo application has been postulated. It led to the necessity for large manufacturing of artificial siRNAs [11], which today constitute the primary business of many businesses.

Barriers to their targets for siRNA

There are many biological obstacles to the efficient activity of RNA in cell lines. Firstly, because siRNAs were *polyanions*, these are still unable to permeate the cellular membranes directly and could only leave the bloodstream via pinocytosis or endocytosis. For achieving the silencing consequence, however, endocytized siRNA should enter the barrier of endosome and leave the cytoplasm or cleave it by *ribonucleases* or escape from the cell via exocytosis. When siRNA reaches the cytoplasmic space, cytoplasmic *ribonucleases* may also be cleared or their concentration can decrease as a result of the division of target cells.

Apart from the specific activity, siRNA may produce a series of untargeted consequences that, because of the toxicity they cause, prohibit their usage at large doses.

Unwanted stimulation of a system of immune system is the main non-target impact of siRNA under the operation of specific motifs in the siRNA strand. Immuno stimulating motives can be accepted by Toll-like receptors (TLR3/7/8, induction of the production of bisphosphonates (α or β) and oxidative stress that trigger immune reaction and cause widespread alterations in the pattern of gene expression whenever interrelating with surface area or present in endosome. Additional non-target effects of siRNAs include the relocation of endogenous RNA from RISC that may interrupt the cell's normal regulatory processes [12]. Comparable effects are possible due to the anti-sense strand of siRNA, which binds to partly identical non-target mRNA, that may be incorporated into RISC* and inhibit the production of non-target mRNA genes. In the final instance, the translation block does not contain mRNA cleavage.

New variables that limit the efficacy of siRNA in transition to organism levels, such as: siRNA filtering via kidneys, siRNA immune system cells, serum endonuclease cleavage, endothelium barrier. Because of the existence of such barriers, siRNA has decreased bioavailability as well as unfavourable pharmacokinetics in vitro, that require the utilization of large doses of the siRNA and should not always allow the preferred impact to be achieved. This review looks at solutions to the above-mentioned issues regarding biochemical modifications of the siRNAs. This includes the introduction of non-natural nucleic acids into siRNA structure as well as the attachment of molecules to siRNA and ensures interaction with biological structures that enhance siRNAs as potential drugs in their efficacy and specificity.

Bioconjugates

The utilization of conjugates as a process of obtaining siRNA to cells regarding the formation of siRNA conjugates through (1) biomolecules that are able to specifically bind membrane receptors, (2) ions that can penetrate the cell via means of natural techniques of transport, or (3) molecules that interact with the cell membrane non-specifically. The connector structure binding the siRNA and molecules, in addition to the type of biogenic molecule, influences the effectiveness of the accumulating and the microbial properties of the siRNA [13]. In specifically, the ability to cleave the linker whenever conjugate entered the cells avoids a reduction in RNAi effectiveness induced to RISC formation restriction. *Disulfide* or *thioether* bonds, pH-sensitive bonds or photosensitive bonds, as bonding bonds, are utilized (Figure 4). Conjugates that include linkers stable in experimental circumstances are extensively utilized and the conjugate structure plays an important function.




Figure 4: A scheme of siRNA bioconjugates [14].

Other RNA Interference Forms

In addition to the natural and produced siRNAs, new papers with alternate forms of both have been published and are mentioned here:

Micro-RNAs Micro: These are a wealth of short RNAs (19–25 nt) expressed in every higher eukaryote. It is encoded inside the host cells and digested in 70nt hairpin precursors by Dicer. Its purpose is to control endogenous expression of genes via inaccurate base pairings and suppression of protein translation throughout development. Recent study has revealed their unique functions in regulating early haematopoiesis and commitment to lineage. Mostly they are called temporal small RNAs as reflecting their significance in the control of the period of growth.

Piwi-Interacting RNAs (pi): These would be 25–31 nt single-stranded RNAs that were recently discovered in rat, mouse, human and rat tests. They showed that Piwi protein (a sub-class of protein called *Argonaute*) and RecQ1 mammalian protein are associated to a Piwi-interacting RNA complex (piRC) [15]. Such complexes are intended to control the genome into sperm cells that mature.

Short-Hairpin RNAs (sh): These are synthesised and designed on the basis of naturally existing miRNAs. It may be articulated via plasmid vectors or introduced into genome endogenously. These vectors include an inverted reiteration of nineteen to twenty nine nucleotides through a sequence of 6-9 base pairs separated from the intended one. Whenever the emerging RNA is manufactured, a stem loop is formed, which may be translated by DICER. Such vectors often utilise pol III promoters, which are usually employed by a cell to drive short RNAs production, e.g. transfer NAs.

Modulatory Small RNAs: These are small, dual-stranded RNAs discovered in the nuclei of the neural mouse stem cells. They serve a crucial function in regulating

neurotransmitter release via the interaction between ds RNA and protein.

CONCLUSION

The incorporation of natural molecules into siRNA is indeed a viable alternative for a non-viral delivering because it has great benefits over several other strategies (techniques, distribution via cationic fats, as well as polymers) in terms of target cell specificity and lack of harmful impacts. The main challenge in customizing bioconjugates seems to be the requirement for application-specific ligands depending on the specifics of ligand-receptor encounters. By this perspective, the utilization of the lipophilic siRNA conjugates becomes lesser specific, as LDL receptors are highly articulated in a range of cell types; even so, this may be advantageous if highest efficiency of delivery with different cell types also isn't needed and aggregation of a drug in non-target cell types doesn't really cause adverse effects. The most recent chemical modification patterns can decrease the ID50 and prolong the biological impact of siRNA conjugates. Due to the consequence, the use of siRNA-induced medicines in the treatment practice is likely to rise significantly over the next few decades.

REFERENCES

- Chen X, Mangala LS, Rodriguez-Aguayo C, et al. RNA interference-based therapy and its delivery systems. *Cancer Metastasis Rev* 2018;37(1):107–124.
- Mahas A, Aman R, & Mahfouz M. CRISPR-Cas13d mediates robust RNA virus interference in plants. *Genome Biol* 2019;20(1):263.
- Olina AV, Kulbachinskiy AV, Aravin AA, et al. Argonaute proteinS and mechanisms of RNA interference in eukaryotes and prokaryotes. *Biokhimiia* 2018;83(5):483–497.
- Airs PM, Bartholomay LC. RNA interference for mosquito and mosquito-borne disease control. *Insects* 2017;8(1).
- Ma M, He W, Xu S, et al. RNA interference in Colorado potato beetle (*Leptinotarsa decemlineata*): A potential strategy for pest control. *J Integr Agric* 2020;19(2):428–437.
- Gutbrod MJ, Martienssen RA. Conserved chromosomal functions of RNA interference. *Nat Rev Genet* 2020;21(5), 311–331.
- Wu K, Taylor CE, Pinheiro DH, et al. Lethal RNA interference response in the pepper weevil. *J Appl Entomol* 2019;143(7):699–705.
- Heigwer, F, Port, F, & Boutros, M. RNA Interference (RNAi) Screening In *Drosophila*. *Genetics* 2018;208(3):853–874.
- Liu H, Xiong LH, Kwok RTK, et al. AIE bioconjugates for biomedical applications. *Adv Opt Mater* 2020;8(14).
- Martínez-Alonso, M, Gasser G. Ruthenium polypyridyl complex-containing bioconjugates. *Coord Chem Rev* 2021;434.
- Han H. RNA interference to knock down gene expression. *Methods mol biol* 2018;1706:293–302.
- Sobecka A, Barczak W, Suchorska WM. RNA interference in head and neck oncology. *Oncol Lett* 2016;12(5): 3035–3040.
- Zhu KY, Palli SR. Mechanisms, applications, and challenges of insect RNA interference. *Annu Rev Entomol* 2020;65:293–311.
- Chernikov IV, Vlassov VV, Chernolovskaya EL. Current development of siRNA bioconjugates: From research to the clinic. *Front Pharmacol* 2019;10:444.
- Sinclair JB, Asgari S. Ross River virus provokes differentially expressed microRNA and RNA interference responses in *Aedes aegypti* mosquitoes. *Viruses*, 2020;12(7).